Veloxis reaches milestone
The Danish biotech Veloxis has applied for marketing authorization from the EMA for a candidate drug aimed at ensuring kidney transplant patients do not reject the new organ.
by Kresten Morten Munksgaard
The European Medicines Authority (EMA) will soon have to decide on whether or not to grant marketing authorization to a new drug from the Danish company Veloxis for the treatment of kidney transplant patients. The Marketing Authorization Application (MAA) is the first ever for the company and the submission signals an important milestone for the Danish biotech.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
